Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis
- 22 May 2010
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 19 (6) , 823-832
Abstract
The objective of this work is to perform a systematic review and meta-analysis of all randomized controlled trials comparing a single intravenous dose of palonosetron (PAL) 0.25 mg with other 5-HT3R in patients receiving moderately or highly emetogenic (MoHE) chemotherapy. Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoints were the incidence of acute and delayed nausea and vomiting. The side effects of each treatment were analyzed. A subgroup analysis was performed to evaluate the influence of the use of corticosteroids. The results are expressed as risk ratio (RR) and the correspondent 95% confidence interval (CI). Five studies were included, with 2,057 patients. PAL was compared with ondansetron, granisetron, and dolasetron. Patients in PAL group had less nausea, both acute (RR = 0.86; CI95% = 0.76 to 0.96; p = 0.007) and delayed (RR = 0.82; CI95% = 0.75 to 0.89; p < 0.00001). They also had less acute vomiting (RR = 0.76; CI95% = 0.66 to 0.88; p = 0.0002) and delayed vomiting (RR = 0.76; CI95% = 0.68 to 0.85; p < 0.00001). There were no statistical differences in side effects like headache (RR = 0.84; CI95% = 0.61 to 1.17; p = 0.30), dizziness (RR = 0.40; CI95% = 0.13 to 1.27; p = 0.12), constipation (RR = 1.29; CI95% = 0.77 to 2.17; p = 0.33) or diarrhea (RR = 0.67; CI95% = 0.24 to 1.85; p = 0.44). Patients receiving PAL presented less nausea and vomiting regardless of the use of corticoids. We found no statistical heterogeneity in the global analysis. PAL was more effective than the other 5-HT3R in preventing acute and delayed CINV in patients receiving MoHE treatments, regardless of the use of concomitant corticosteroids.Keywords
This publication has 51 references indexed in Scilit:
- The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trialSupportive Care in Cancer, 2008
- Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapyCurrent Opinion in Supportive & Palliative Care, 2008
- Emerging drugs for chemotherapy-induced emesisExpert Opinion on Emerging Drugs, 2006
- Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteersCurrent Medical Research and Opinion, 2005
- Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoeaThe Lancet Oncology, 2005
- Monitoramento e avaliação dos efeitos colaterais da quimioterapia em pacientes com câncer de cólonRevista Latino-Americana de Enfermagem, 2004
- PalonosetronDrugs, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Antiemetic guidelines: creating a more practical treatment approachSupportive Care in Cancer, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986